Lund, Sweden, 29 May 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today are proud to announce that Renée Aguiar-Lucander, CEO, Hansa Biopharma has been named one of Sweden’s Most Influential Business Women of 2026 by Dagens industri. This nomination recognizes leaders with significant influence over the development, competitiveness and future of Swedish business. The […]
Lund, Sweden, 18 May. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, be participating in a panel discussion titled “Scaling Success: Key Drivers for Growing Nordic Biotechs” at the LSX Nordic Congress, in Copenhagen, at 13:10 CEST on Tuesday 19 , 2026. Read more…
Mike Ward, Global Head of Thought Leadership at Decision Resources Group, part of Clarivate, chaired a panel of top industry executives at the Anglonordic Life Sciences Conference: Renee Aguiar-Lucander, CEO Calliditas Therapeutics, Steven Powell, CEO eTheRNA immunotherapies and Roel Bulthuis, Managing Partner at INKEF Capital, shared key decisions that shaped the fate of their various […]
Since taking over as CEO of Calliditas Therapeutics in 2017, Renee Aguiar-Lucander has taken the biotech through an IPO in Stockholm and commenced a pivotal phase 3 trial plus major licensing deals and a secondary fund raise. She has established a US presence, made transformational regulatory milestones, and this month completed a successful upsized US […]
